Your browser doesn't support javascript.
loading
Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab.
van der Schoot, Lara S; Atalay, Selma; Otero, Marisol E; Kievit, Wietske; van den Reek, Juul M P A; de Jong, Elke M G J.
Affiliation
  • van der Schoot LS; Department of Dermatology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Atalay S; Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Otero ME; Department of Dermatology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Kievit W; Department of Dermatology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • van den Reek JMPA; Department for Health Evidence, Radboud University Medical Center, Nijmegen, the Netherlands.
  • de Jong EMGJ; Department of Dermatology, Radboud University Medical Center, Nijmegen, the Netherlands.
Br J Dermatol ; 187(6): 1028-1030, 2022 12.
Article in En | MEDLINE | ID: mdl-35895852
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Biological Products Limits: Humans Language: En Journal: Br J Dermatol Year: 2022 Document type: Article Affiliation country: Netherlands Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Biological Products Limits: Humans Language: En Journal: Br J Dermatol Year: 2022 Document type: Article Affiliation country: Netherlands Country of publication: United kingdom